Our investigational drug candidate, nelotanserin, is a selective inverse agonist of the 5HT2A receptor.i*

Nelotanserin is being studied in patients with DLB or PDD who are experiencing REM sleep behavior disorder (RBD), in which they physically act out their dreams, impacting their quality of life and endangering their bed partners. In addition, we are evaluating other opportunities for nelotanserin in patients with DLB.

* Nelotanserin in not yet approved for any indication in any market.

References

  1. Wen W, Ramaswamy S, Piscitelli S, Friedhoff L. Examining the clinical profile of nelotanserin, a novel agent in development for Lewy body dementia. Am J Geriatr Psychiatry. 2017;25(3)(suppl):S129-S130. http://www.ajgponline.org/article/S1064-7481(17)30165-3/fulltext. Accessed August 16, 2017.